Global Neoantigen Cancer Vaccine Market

Global Neoantigen Cancer Vaccine market overview.

The Global Neoantigen Cancer Vaccine Market is projected to develop with a CAGR of 54.19% throughout the forecast period and is expected to reach USD 1754 million by 2027 from USD 804 Million in 2020. Rapid technological improvements and infrastructural trends withinside the healthcare industry are driving the growth of the neoantigen cancer vaccines market. Increased investment by government and healthcare professionals is also expected to contribute to the global growth of the neoantigen cancer vaccines market in the coming years. Furthermore, the increase in cancer cases is expected to drive market growth till 2028. The prevalence of cancer is increasing all over the world. In addition, significant external funding is required to complete the research and development project. These elements stimulate the market for neoantigen cancer vaccines and performance-based pricing that hinders the global market growth.

What is Neoantigen Cancer Vaccine?

Neo-antigens are tumor-specific antigens made up of mutated proteins found only in cancer cells. The neoantigen cancer vaccine stimulates the immune system to produce cytotoxic T lymphocytes (CTL), which attack the neoantigen-based cancer cells and help clear the tumor. Tumors may cause the increase in neoantigens with high TMB and MSI / MMR. The vaccine against neoantigen cancer allows the destruction of cancer cells while healthy cells are left alone. Vaccines based on neoantigens than the traditional AATs have several advantages. For starters, since neoantigens are only expressed by tumor cells, they can elicit truly tumor-specific T cell responses, thereby preventing damage to non-malignant tissue. According to the researchers, several viruses have been linked to cancer. The human papillomavirus (HPV), for example, can motive cervical cancer and lots of other cancers.

GROWTH DRIVER

Rapid technological innovations

Neoantigens are distinctly immunogenic since they’re now no longer expressed in everyday tissues. They can activate CD4 + and CD8 + T cells to generate an immune response and have the potential to become new targets for tumor immunotherapy. The development of bioinformatics technology has accelerated the growth of neoantigens cancer vaccines worldwide.

Growing investments from government agencies and healthcare providers

Due to overspreading of cancer worldwide, government agencies and healthcare providers are investing a huge amount in the market, which is the major factor driving the neoantigen vaccine market.

Infrastructural Trends

Infrastructural development in the healthcare industry and Health infrastructure pertains to all physical infrastructure, non-clinical equipment, shipping and era infrastructure (which includes ICT [Information and Communication Technologies]) required for powerful shipping of services leads to the growth of the neoantigen cancer vaccine market globally.

PRE COVID 19 IMPACT

The global neoantigen cancer vaccine market was growing at a good phase pre covid due to maintaining the same growth rate from 2015-2019 because the rapid technological advancements and infrastructural developments in the healthcare industry were driving the growth of the neoantigen cancer vaccines market.

COVID-19 IMPACT

The neoantigen cancer vaccine market has suffered a significant setback in growth due to the sudden outbreak of COVID19. As the number of COVID19 cases rises, health systems worldwide have focused on controlling the disease, ignoring the prevention, diagnosis and treatment of other chronic diseases such as cancer. As a result, the neoantigen cancer vaccines market is expected to be negatively impacted.

POST COVID-19 IMPACT

Due to the easing of regulations and the resumption of R & D’s commercial enterprise and scientific trials for cancer vaccines, the market is predicted to advantage traction in the coming years. The rise in cancer cases is expected to drive the market growth till 2027. The prevalence of cancer is increasing worldwide. In addition, significant external funding is required to complete the research and development project. These elements are driving the market for neoantigen cancer vaccines and performance-based pricing, which is hampering the growth of the global market.

PRODUCT TYPE SEGMENTAL ANALYSIS

 The market is divided into Personalized NeoAntigen Vaccine and Neoantigen OffTheShelf Vaccine. These vaccines are made from DNA. Personalized Neo Antigen is expected to dominate the market during the forecast period.

NEOANTIGEN TYPE SEGMENTAL ANALYSIS

Based on Neoantigen type, the Neoantigen cancer vaccine market is segmented into Nucleic Acid, Dendritic Cell, Tumor Cell, and Synthetic Long Peptide.

ROUTE OF ADMINISTRATION SEGMENTAL ANALYSIS

 The market is segmented into intravenous, intramuscular, transdermal, etc. The intravenous segment will dominate the market up to 2027, and intramuscular is planned to be the fastest-growing segment of the forecast period since intravenous is injected directed into the muscles of human beings. This growth can be attributed to rapid response and the fact that it can easily control the dosage of the drug. Along with this, intramuscular injections can be used rather than intravenously, as some drugs irritate the veins when injected intravenously—strong growth in the intramuscular routes of administration segment in the coming years.

CELL TYPE SEGMENTAL ANALYSIS

Based on cells, the market is segmented into Autologous and Allogenic. An autologous cell transplant uses healthy blood stem cells out of your body to update diseased or broken bone marrow. In an allogeneic transplant, stem cells are accumulated from an identical donor and transplanted into the affected person to suppress the ailment and repair the affected person’s immune system. An allogeneic stem cell transplant isn’t the same as an autologous stem cell transplant, which makes use of stem cells from the patient’s very own body.

TECHNOLOGY SEGMENTAL ANALYSIS

Based on technology, the neoantigen cancer vaccine market is segmented into Whole Genome Sequencing, RNA Sequencing, HLA Typing. Whole-genome sequencing (WGS) is a complete technique for reading whole genomes. Genomic statistics have been instrumental in figuring out inherited disorders, characterizing the mutations that pressure most cancers’ progression, and monitoring ailment outbreaks. RNA-seq (RNA-sequencing) is a way to study the amount and sequences of RNA in a pattern using next-era sequencing (NGS). It analyzes the transcriptome, indicating which of the genes encoded in our DNA are became on or off and to what extent.

DELIVERY MECHANISM SEGMENTAL ANALYSIS

Based on delivery Mechanism, the market is segmented into Gene gun, Electroporation, Liposomes, Virosomes, Others. Electroporation is a microbiology method wherein an electrical area is carried out to cells so that you can grow the permeability of the cell membrane, permitting chemicals, drugs, electrode arrays, or DNA to be delivered into the cell.

APPLICATION SEGMENTAL ANALYSIS

 Topic (OSE2101) is used in the remedy of HLA-A2+ Lung cancer (NSCLC) patients. The application segment is segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer section will dominate the market within the forecast period because of the neoantigen-based immunotherapy of OSE Immunotherapeutic, which is in improvement for the Tedopi (OSE2101) neoantigen cancer vaccine is anticipated to release in 2022. Currently, the vaccine is in section III degree of scientific improvement.

REGION SEGMENTAL ANALYSIS

 The market is segmented into North America, Europe, Asia-Pacific, South America, Middle East, and Africa. Regionally, the Asia Pacific neoantigen cancer vaccine market is predicted to be the main region over the forecast period because of the growing incidence and occurrence of lung cancer, melanoma, gastrointestinal, pancreatic cancer and different strong tumor indications.

COMPETITOR ANALYSIS

Major players running in the Global Neoantigen Cancer Vaccine Market are OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG, amongst others are the main players running withinside the Global Neoantigen Cancer Vaccine Market. The businesses running in the market throughout the globe are focusing extra closer to increasing their proportion withinside the market.

KEY STAKEHOLDERS

• Market research and consulting firms
• Industry Associations
• Global Neoantigen Cancer Vaccine market manufacturing firms
• Research Organizations and consulting companies
• Regulatory Bodies
• Suppliers
• Retailers

RECENT DEVELOPMENTS

1) BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) nowadays introduced the two businesses have entered right into a buy settlement for BioNTech to accumulate Kite’s strong tumor neoantigen T cell receptor (TCR) R&D platform and scientific production facility in Gaithersburg, MD. The acquired Gaithersburg facility will offer manufacturing ability to guide scientific trials in the United States and supplement BioNTech’s current cell remedy production facility in Idar-Oberstein, Germany. The facility will guide the improvement of BioNTech’s increasing pipeline of novel cell therapies, inclusive of most cancers product applicants primarily based totally on its CAR-T cell amplifying mRNA vaccine (CARVac) and NEOSTIM systems in addition to the newly received individualized neoantigen TCR program.

2) Moderna, Inc., (Nasdaq: MRNA), a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to create a brand new era of transformative drugs for patients, nowadays shared in-between period records from the expansion cohort of its ongoing Phase 1 study of the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157 in mixture with Merck’s Keytruda®1 at The Society for Immunotherapy of Cancer’s Annual Meeting (SITC 2020). The dose expansion cohort protected ten patients with HPV(-) Head and Neck Squamous Cell Carcinoma (HNSCC) and 17 patients with Micro-Satellite Stable Colorectal Cancer (MSS-CRC).

 3) Pfizer Oncology strives to enhance cancer biology’s frontiers and translate this know-how into high-effect drugs for cancer patients. Our main areas of interest include Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; Integrative Biotechnology, and Immuno- Oncology. In Tumor Cell Biology, we are focused on oncogenic drivers, tumor metabolism, and epigenetics. Precision Medicine represents an included cluster of generation systems and translational technological know-how configured to permit patient-tailored, hypothesis-pushed experimental medicinal drug approaches. Our Integrative Biotechnology Group helps novel goal identity and validation thru purposeful genomics, proteomics, and other “omics” approaches.

Scope of the Report

Market Modelling

By Type

• Wrought Alloys
• Cast Alloys
• Others

By Application

• Construction
• Aerospace and Defense
• Machinery
• Marine
• Packaging
• Transportation
• Electrical
• Others

By Strength

• High Strength
• Ultra-High Strength

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Report Content

1. Research Strategic Development

           1.1 Market Modelling

           1.2 Product Analysis

           1.3 Market Trend and Economic Factor Analysis

           1.4 Market Segmental Analysis

           1.5 Geographical Mapping

          1.6 Country Wise Segregation

2. Research Methodology

       2.1 Identification of Targeted Market

       2.2 Data Acquisition

       2.3 Refining of Data/ Data Transformations

       2.4 Data Validation through Primary Techniques

       2.5 Exploratory Data Analysis

       2.6 Graphical Techniques/ Analysis

       2.7 Quantitative Technique Analysis

       2.8 Visual Result/ Presentation

3. Executive Summary
4. Market Insights

      4.1 Supply Chain Analysis

      4.2 Economic Factor Analysis

           4.2.1 Drivers

           4.2.2 Trends

           4.2.3 Opportunities

           4.2.4 Challenges

     4.3 Technological Landscape

     4.4 Competitors and Product Analysis

     4.5 Regulatory Framework

     4.6 Company Market Share Analysis, 2020

     4.7 Porter’s Five Forces Analysis

     4.8 New Investment analysis 

     4.9 PESTEL Analysis

     4.10 Pre Covid Impact

     4.11 Covid-19 Impact

     4.11 Post Covid Impact

5. Global Neoantigen Cancer Vaccine Market Overview

   5.1 Market Size & Forecast, 2017-2027

         5.1.1  Demand

             5.1.1.1 By Value (USD Million)

   5.2 Market Share & Forecast,2017-2027.

      5.2.1 By Product Type

        5.2.1.1 Personalized Neoantigen Vaccine

        5.2.1.1 Neoantigen Off-the-shelf Vaccine

     5.2.2 By Neoantigen Type

        5.2.2.1 Nucleic Acid

        5.2.2.2 Dendritic Cell

        5.2.2.3 Tumor Cell

        5.2.2.4 Synthetic Long Peptide

     5.2.3 By Route of Administration

       5.2.3.1 Intravenous

       5.2.3.2 Intramuscular

       5.2.3.3 Transdermal

       5.2.3.4 Others

   5.2.4 By Cell Type

       5.2.4.1 Autologous

       5.2.4.2 Allogenic

   5.2.5 By Technology

       5.2.5.1 Whole Genome Sequencing

     5.2.5.2 RNA Sequencing

     5.2.5.3 HLA typing

  5.2.6 By Delivery Mechanism

     5.2.6.1 Gene gun

     5.2.6.2 Electroporation

     5.2.6.3 Liposomes

     5.2.6.4 Virosomes

     5.2.6.5 Others

  5.2.7 By Mechanism

     5.2.7.1 Lung

     5.2.7.2 Melanoma

     5.2.7.3 Gastrointestinal

     5.2.7.4 Brain Cancer

     5.2.7.5 Others

    5.2.8 By Region

       5.2.8.1  North America

       5.2.8.2 Europe

       5.2.8.3 Asia Pacific

       5.2.8.4 South America

       5.2.8.5 Middle East & Africa

6. North America Neoantigen Cancer Vaccine Market Overview Market Overview

  6.1 North America Neoantigen Cancer Vaccine Market Size & Forecast 2017-2027

        6.1.1 Demand

            6.1.1.1 By Value (USD Million)

    6.2  North America Neoantigen Cancer Vaccine Market Share & Forecast 2017-2027

     6.2.1 By Product Type

        6.2.1.1 Personalized Neoantigen Vaccine

        6.2.1.2 Neoantigen Off-the-shelf Vaccine

     6.2.2 By Neoantigen Type

        6.2.2.1 Nucleic Acid

        6.2.2.2 Dendritic Cell

        6.2.2.3 Tumor Cell

        6.2.2.4 Synthetic Long Peptide

     6.2.3 By Route of Administration

       6.2.3.1 Intravenous

       6.2.3.2 Intramuscular

       6.2.3.3 Transdermal

       6.2.3.4 Others

     6.2.4 By Cell Type

       6.2.4.1 Autologous

       6.2.4.2 Allogenic

   6.2.5 By Technology

      6 .2.5.1 Whole Genome Sequencing

     6.2.5.2 RNA Sequencing

     6.2.5.3 HLA typing

  6.2.6 By Delivery Mechanism

     6.2.6.1 Gene gun

     6.2.6.2 Electroporation

     6.2.6.3 Liposomes

     6.2.6.4 Virosomes

     6.2.6.5 Others

  6.2.7 By Mechanism

     6.2.7.1 Lung

     6.2.7.2 Melanoma

     6.2.7.3 Gastrointestinal

     6.2.7.4 Brain Cancer

     6.2.7.5 Others

 6.2.8 By Country

        6.2.8.1 US

        6.2.8.2 Canada

        6.2.8.3 Mexico

  6.3 Company Market Share

  6.4 Economic impact study on Neoantigen Cancer Vaccine Market North America

7. Europe Neoantigen Cancer Vaccine Market Overview

       7.1 Europe Neoantigen Cancer Vaccine Market Size & Forecast 2017-2027

             7.1.1 Demand

                7.1.1.1 By Value (USD Million)

      7.2  Europe Neoantigen Cancer Vaccine Market Share & Forecast 2017-2027

      7.2.1 By Product Type

        7.2.1.1 Personalized Neoantigen Vaccine

        7.2.1.2 Neoantigen Off-the-shelf Vaccine

     7.2.2 By Neoantigen Type

        7.2.2.1 Nucleic Acid

        7.2.2.2 Dendritic Cell

        7.2.2.3 Tumor Cell

        7.2.2.4 Synthetic Long Peptide

     7.2.3 By Route of Administration

       7.2.3.1 Intravenous

       7.2.3.2 Intramuscular

       7.2.3.3 Transdermal

       7.2.3.4 Others

     7.2.4 By Cell Type

       7.2.4.1 Autologous

       7.2.4.2 Allogenic

   7.2.5 By Technology

      7 .2.5.1 Whole Genome Sequencing

     7.2.5.2 RNA Sequencing

     7.2.5.3 HLA typing

  7.2.6 By Delivery Mechanism

     7.2.6.1 Gene gun

     7.2.6.2 Electroporation

     7.2.6.3 Liposomes

     7.2.6.4 Virosomes

     7.2.6.5 Others

  7.2.7 By Mechanism

     7.2.7.1 Lung

     7.2.7.2 Melanoma

     7.2.7.3 Gastrointestinal

     7.2.7.4 Brain Cancer

     7.2.7.5 Others  

    7.2.8 By Country

        7.2.8.1 Germany

        7.2.8.2 UK

        7.2.8.3 France

        7.2.8.4 Italy

        7.2.8.5 Rest Of Europe

    7.3 Company Market Share

    7.4 Economic impact study on Neoantigen Cancer Vaccine Market Europe.

8. Asia Pacific Neoantigen Cancer Vaccine Market Overview

       8.1 Asia Pacific Neoantigen Cancer vaccine Market Size & Forecast 2017-2027

             8.1.1 Demand

                8.1.1.1 By Value (USD Million)

       8.2 Asia Pacific Neoantigen Cancer Vaccine Market Share & Forecast 2017-2027

       8.2.1 By Product Type

        8.2.1.1 Personalized Neoantigen Vaccine

        8.2.1.2 Neoantigen Off-the-shelf Vaccine

     8.2.2 By Neoantigen Type

        8.2.2.1 Nucleic Acid

        8.2.2.2 Dendritic Cell

        8.2.2.3 Tumor Cell

        8.2.2.4 Synthetic Long Peptide

     8.2.3 By Route of Administration

       8.2.3.1 Intravenous

       8.2.3.2 Intramuscular

       8.2.3.3 Transdermal

       8.2.3.4 Others

     8.2.4 By Cell Type

       8.2.4.1 Autologous

       8.2.4.2 Allogenic

   8.2.5 By Technology

      8 .2.5.1 Whole Genome Sequencing

     8.2.5.2 RNA Sequencing

     8.2.5.3 HLA typing

  8.2.6 By Delivery Mechanism

     8.2.6.1 Gene gun

     8.2.6.2 Electroporation

     8.2.6.3 Liposomes

     8.2.6.4 Virosomes

     8.2.6.5 Others

  8.2.7 By Mechanism

     8.2.7.1 Lung

     8.2.7.2 Melanoma

     8.2.7.3 Gastrointestinal

     8.2.7.4 Brain Cancer

     8.2.7.5 Others  

  8.2.8 By Country

        8.2.8.1 China

        8.2.8.2 India

        8.2.8.3 Japan

        8.2.8.4 Australia

        8.2.8.5 Rest Of Asia Pacific

    8.3 Company Market Share

  8.4 Economic impact study on Global Neoantigen Cancer Vaccine Market Asia Pacific.

9. South America Neoantigen Cancer Vaccine Market Overview

       9.1 South America Neoantigen Cancer Vaccine Market Size & Forecast 2017-2027.

             9.1.1 Demand

                9.1.1.1 By Value (USD Million)

      9.2 South America Neoantigen Cancer Vaccine Market Share & Forecast 2017-2027

     9.2.1 By Product Type

        9.2.1.1 Personalized Neoantigen Vaccine

        9.2.1.2 Neoantigen Off-the-shelf Vaccine

     9.2.2 By Neoantigen Type

        9.2.2.1 Nucleic Acid

        9.2.2.2 Dendritic Cell

        9.2.2.3 Tumor Cell

        9.2.2.4 Synthetic Long Peptide

     9.2.3 By Route of Administration

       9.2.3.1 Intravenous

       9.2.3.2 Intramuscular

       9.2.3.3 Transdermal

       9.2.3.4 Others

     9.2.4 By Cell Type

       9.2.4.1 Autologous

       9.2.4.2 Allogenic

   9.2.5 By Technology

      9 .2.5.1 Whole Genome Sequencing

     9.2.5.2 RNA Sequencing

     9.2.5.3 HLA typing

  9.2.6 By Delivery Mechanism

     9.2.6.1 Gene gun

     9.2.6.2 Electroporation

     9.2.6.3 Liposomes

     9.2.6.4 Virosomes

     9.2.6.5 Others

  9.2.7 By Mechanism

     9.2.7.1 Lung

     9.2.7.2 Melanoma

     9.2.7.3 Gastrointestinal

     9.2.7.4 Brain Cancer

     9.2.7.5 Others  

  9.2.8 By Region

        9.2.8.1 Brazil

        9.2.8.2 Argentina

        9.2.8.3 Rest of South America

 9.3 Company Market Share

  9.4 Economic impact study on Neoantigen Cancer Vaccine Market South America.

10. Middle East & Africa Neoantigen Cancer Vaccine Market Overview

       10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size & Forecast 2017-2027

             10.1.1 Demand

                10.1.1.1 By Value (USD Million)

        10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Share & Forecast 2017-2027

     10.2.1 By Product Type

        10.2.1.1 Personalized Neoantigen Vaccine

        10.2.1.2 Neoantigen Off-the-shelf Vaccine

     10.2.2 By Neoantigen Type

        10.2.2.1 Nucleic Acid

        10.2.2.2 Dendritic Cell

        10.2.2.3 Tumor Cell

        10.2.2.4 Synthetic Long Peptide

     10.2.3 By Route of Administration

       10.2.3.1 Intravenous

       10.2.3.2 Intramuscular

       10.2.3.3 Transdermal

       10.2.3.4 Others

     10.2.4 By Cell Type

       10.2.4.1 Autologous

       10.2.4.2 Allogenic

   10.2.5 By Technology

      10 .2.5.1 Whole Genome Sequencing

     10.2.5.2 RNA Sequencing

     10.2.5.3 HLA typing

  10.2.6 By Delivery Mechanism

     10.2.6.1 Gene gun

     10.2.6.2 Electroporation

     10.2.6.3 Liposomes

     10.2.6.4 Virosomes

     10.2.6.5 Others

  10.2.7 By Mechanism

     10.2.7.1 Lung

     10.2.7.2 Melanoma

     10.2.7.3 Gastrointestinal

     10.2.7.4 Brain Cancer

     10.2.7.5 Others  

  10.2.6 By Country       

        10.2.6.1 Saudi Arabia

        10.2.6.2 UAE  

        10.2.6.3 South Africa

        10.2.6.4 Rest of middle East & Africa

    10.3 Company Market Share

 10.4 Economic impact study on Neoantigen Cancer Vaccine Market Overview Middle East & Africa.

11. Competitor Analysis

    11.1 Company Description (Overview)

    11.2 Financial Analysis

    11.3 Key Products

    11.4 Key Management Personnel

    11.5 Contact Address

    11.6 SWOT Analysis

12. Company Profile

   12.1 Introduction

    12.1.1 OSE Immunotherapeutics SA

   12.1.2 Gritstone bio, Inc

   12.1.3 BioNTech SE

   12.1.4 F Hoffmann-La Roche Ltd

   12.1.5 Pfizer Inc

    12.1.6 Merck & Co Inc

    12.1.7 Moderna Inc

    12.1.8 Avidea Technologies, Inc

    12.1.9 Eli Lilly and Company

   12.1.10 Vaccibody AS

   12.1.11 Agenus Inc

   12.1.12 Novogene Co, Ltd

   12.1.13 ZIOPHARM Oncology Inc

   12.1.14 ISA Pharmaceuticals BV

   12.1.15 BrightPath Biotherapeutics Co, Ltd

   12.1.16 Vaximm AG

   12.1.17 Medigene AG

   12.1.18 Genocea Biosciences Inc

   12.1.19 Advaxis, Inc

   12.1.20 Nouscom AG